Thursday, January 28, 2021

Analytical Method Development Approach When Compound Don’t Have UV Chromophore


High performance liquid chromatography (HPLC) is one of the most important instruments used in pharmaceutical industry. Most of the pharmacopeial monographs methods is based on HPLC with UV-Visible detector and It is useful analytical technique for the qualitative and quantitative purpose. In some of compound there is lack of or absence of chromophore which result into low UV absorption or no UV absorption. Chromophores are light abso
rbing group that allows detection of analytes.

When there is low or no chromophore in that case it’s very challenging to detect at low concentrations or even at higher content of molecule.

Following are some methods which can be used to enhance the UV detection:

1.  Non-chromophoric compounds can be analysed by using suitable derivatising agent which will be UV active with the help of UV-Visible detector. Before starting derivatisation method development, sample must be achirally pure. Procedure of pre-column derivatization is challenging hence it’s problematic and inconvenient method to reproduce.

2.   Regular derivatization of chiral compounds is not recommended as it will cause racemisation. Even addition of any reagent in mobile phase may cause reduction of resolution in enantiomer. Hence need to use a chiral derivatization reagent for chiral compounds. Use of 5% beta-cyclodextrine in mobile phase to improve the selectivity of enantiomers.

3.   Post column derivatisation technique is used by adding the correlated compound through a T-junction allows to adjust the background absorbance to match the concentration of analyte. The sensitivity of the method will be depending on the final absorbance of the related mobile phase by optimise flow rate.

4.    Addition of reagent to form the complex with formation of colour which can be detected in visible range.

For more information visit - https://veeprho.com/blog/analytical-method-development-approach-when-compound-dont-have-uv-chromophore/


Wednesday, January 27, 2021

Drug-Excipient Compatibility Study

 


What is drug-excipient compatibility?

Drug-excipient compatibility study is very much important stage of formulation development of drug product in combination of excipients. It’s significant phase of pre-formulation study. Drug product not only contains active pharmaceutical ingredient (API) but it’s combination of different forms of excipients. it’s important to study the physical and chemical interaction between API and excipient. Generally, for excipient compatibility study combination of binary mix in ratio of 1:1 is assessed. In some instances, to check the extreme interaction and complications, multiple excipient mixture in presence of API were appraised.

Importance of excipients and it’s compatibility with API:

Selection of appropriate excipients could be done by performing the drug excipient compatibility study. It supports to prevent the expected last-minute complications throughout the process of formulation development.

Role of excipients is important in formulations development of active ingredient into effective drug product. Excipients enhance the essential quality of the drug product such as exact required dosage, stability, solubility, performance, acceptability, quality, absorption of the drug in vivo, safety and efficacy. As per regulatory requirements drug-excipient compatibility study require to predict probable degradation pathways of the drug product. This study supports to recognize the selection of appropriate excipients and helps to understand the interaction between drug and excipients and the storage condition of the product.

Interaction of drug-excipients:

Drug-excipient compatibility complications obtain from the direct reactions amongst API and excipients or by the presence of responsible impurities in the excipients. Interaction between excipient and the presence of sensitive functional group of API results into incompatibility of drug-excipients compatibility study. Degradation of drug in presence of excipients lead to formation of impurities and to identify these impurities need complete understanding of the reaction and sufficient analytical details. Analytical characterization data helps to understand the possible degradation pathway of API.  

Following are the some of the typical process of drug-excipient compatibility which may impact the drug product stability in presence of excipient.

Physical interactions,

Chemical interactions,

Physiological interactions,

For more information visit https://veeprho.com/blog/drug-excipient-compatibility-study/


What is Out of-Specification Investigation and How to Proceed for it?




Background:

FDA issued warning letter to the most of the drug substance and drug product manufacturer. During the inspection, FDA find out the fault, the way investigation of OOS had been carried out by the manufacturer. There is no proper investigation of OOS outcome. FDA warning letters often found that the procedure for handling of OOS is lacking or poorly scripted. It is very much important to know that how to meet the current regulatory expectation for OOS investigation. However, a specific and well drafted adequate OOS SOP is important for through investigation procedure assure an ample investigation. 

What is Out‑of-Specification (OOS):

When analytical results that does not meets the pre-established acceptance criteria of in-house test specification or official pharmacopeial monograph specification range then it termed as Out‑of-Specification results. OOS results may be observed during the analysis of packing materials, raw materials, excipients, drug substance, in-process or final drug products testing and stability study analysis. All ambiguous results which observed out of set specification is named as OOS results.

Investigation of Out‑of-Specification Results:

The main aim of OOS investigation should be focus on the definite outcome of the root cause for the OOS result. OOS SOP is very much important to conclude appropriate investigation. The investigation must be on time and competent enough to conclude it’s root cause identification, impact evaluation and finding efficient corrective action and preventive action’s. Most of the organization have OOS SOP but either it may not appropriate or not followed properly. There is no through investigation carried out and no root cause investigations had been carried out for these OOS results.

When OOS is observed then systematic investigation need to be done to check if there is an appropriate root cause. Prior to proceeding for proper OOS investigation need to cross check analytical error methodically and confirm the initial test results by repeating the analysis with the original sample and solutions.

Following is the important steps for performing the OOS investigations:

OOS may be observed due to the following errors but not restricted to these factors.

1.       Error related to analytical laboratory:


2.       Analytical instruments or equipment’s used for analysis is not in valid calibration state.

3.       Analytical test procedure not followed properly.

4.       Analyst Error,

5.       Error while doing calculations,

6.       Error due to the instrument failure.

7.       Test sample is not uniform or homogenous:


8.       Sampling error i.e. sample is not uniform or proper

9.       Pooling of sample is not appropriate

10.   Error at the time of sample handling

11.   Manufacturing process related error:


12.   Quality of used excipients, raw materials or intermediates,

13.   Operator error,

14.   Validated procedure not followed correctly or Deviation from the standard procedure,

15.   At the time of manufacturing in-process check or control not done properly,

16.   Error due to the equipment failure.

For more information visit https://veeprho.com/blog/what-is-out-of-specification-investigation-and-how-to-proceed-for-it/

Monday, January 18, 2021

Effects of Impurities in Pharmaceuticals

 


Impurities may bring about incompatibility with other substances. Impurities may lower the shelf life of the substances. Impurities may cause difficulties during formulations and use of the substances. Sometimes Impurities change the physical and chemical properties of the substances. Impurities present in a solid organic compound tend to have 2 effects on the melting point. First, they tend to lower the overall melting point of the compound versus the value for pure material. Second, they tend to increase the range of the melting point values.

Complete Blog on : https://veeprho.com/blog/effects-of-impurities-in-pharmaceuticals/

Wednesday, January 13, 2021

Regulatory Requirement for Stability Study

Regulatory Requirement for Stability Study

Introduction:

Pharmaceutical products shelf-life estimation by assessing through systematic stability study is regulatory requirement, during this review current regulatory requirements elaborated.

The main aim of this study is to produce indication about how the drug substance and drug product quality is changes with time by exposed to different climate conditions like temperature, humidity and photolytic condition. Stability study helps to established retest period for the drug substance and validity of drug product and proposed storage conditions and proves that it meets it’s set specifications.

What is Stability?

Stability defines as, “The formulated products remains stable during it’s period within it’s physical, chemical, microbiological, pharmacological and medicinal specification in its designated packaging state”. Stability study is vital requirement to prove the safety and efficacy of pharmaceutical drug substances and drug products.

Drug Metabolite Impurities, Pathways & Analytical Techniques

  Metabolites   are the intermediate products of metabolic reactions catalyzed by various enzymes that naturally occur within cells. The ter...